Related Experiment Video

Updated: Jun 25, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Targeting RAS signalling pathways in cancer therapy

Julian Downward1

  • 1Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK. julian.downward@cancer.org.uk

Nature Reviews. Cancer
|January 2, 2003
PubMed

Insights

RAS proteins regulate cell growth and are often altered in human tumors. Targeting these RAS pathways offers a promising strategy for developing new cancer therapies to inhibit tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signalling

Background:

  • RAS proteins are crucial regulators of cell signaling pathways.
  • Aberrant RAS signaling is implicated in the development and progression of most human cancers.
  • Mutations in RAS genes or alterations in associated signaling components lead to uncontrolled cell growth.

Purpose of the Study:

  • To review the role of RAS proteins in cell growth and malignant transformation.
  • To discuss the therapeutic potential of targeting RAS signaling pathways in cancer treatment.
  • To highlight emerging therapeutic agents targeting the RAS pathway.

Main Methods:

  • Literature review of studies on RAS protein function and cancer.
  • Analysis of current therapeutic strategies targeting RAS pathways.
  • Overview of clinical trial data for novel RAS-targeted agents.

Main Results:

  • RAS pathway dysregulation is a common driver in human malignancies.
  • Targeting RAS signaling demonstrates potential for inhibiting tumor growth, survival, and metastasis.
  • Several novel therapeutic agents targeting RAS pathways are progressing through clinical development.

Conclusions:

  • The RAS signaling network is a critical target for cancer therapy.
  • Targeted therapies offer a rational approach to combatting RAS-driven cancers.
  • Ongoing research and development hold promise for improved patient outcomes in various cancers.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...